News | May 31, 2021
Sun Pharmaceutical’s internals remain strong: ICICI Securities
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
Adjusted PAT declined 18.8% YoY
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The patients can check to see if the product purchased by them is genuine or not by scratching the surface and verifying the code through the app or the website
The GMP certificate is valid for three years until April 2024.
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021
Cocktails of 2 mAbs based products are better equipped to deal with variants than single mAb based products which have a tendency of losing their efficacy with rapidly generating variants
Subscribe To Our Newsletter & Stay Updated
